Mayo clinic tests tailored obesity drugs for bipolar patients

NCT ID NCT07213466

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether matching specific weight-loss medications (Wegovy, Contrave, or Qsymia) to a person's obesity type (e.g., 'hungry brain' or 'emotional hunger') helps people with bipolar disorder lose weight safely. One hundred adults with bipolar or schizoaffective disorder will take part in a 20-week program that includes group therapy and regular check-ins. The goal is to see if this personalized approach is feasible and well-tolerated.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
semaglutide, naltrexone/bupropion, or phentermine/topiramate
What this could lead to
If successful, this could help doctors choose the right weight-loss medication for people with bipolar disorder, improving weight management without worsening mood symptoms.
What could go wrong
This is a small, early-phase feasibility study (100 people) with no placebo control for all groups. Results may not apply to everyone, and weight-loss drugs can cause side effects or interact with mood stabilizers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPOLAR I DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.